OXFORD, England – UK-based Green Biologics Ltd., a technology developer and emerging bio-based C4 chemicals producer focused on renewable n-butanol, has closed a £15.4 million (approximately $25 million) Series B round led by Sofinnova Partners with strategic participation by Swire Pacific Limited.

“We are pleased to welcome Sofinnova Partners as our lead investor and Swire Pacific as a new strategic investor, and we appreciate the continued support of our existing investors.” said Sean Sutcliffe, GBL Chief Executive. “As well as bringing exceptional skills and experience from our new investors to accelerate the development of the company, this investment round underlines the strength of Green Biologics' commercial and technical position and will allow us to execute our plan to bring on-stream our first commercial production facility in the U.S. in 2016,” said Sutcliffe.